Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer

Sarah Derks; Hanneke W. M. van Laarhoven

doi:https://doi.org/10.1177/17588359221142788

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer

Sarah Derks, Hanneke W. M. van Laarhoven

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Citation (Scopus)

Original language	English
Journal	Therapeutic advances in medical oncology
Volume	14
DOIs	https://doi.org/10.1177/17588359221142788
Publication status	Published - 1 Jan 2022

Keywords

checkpoint inhibitor
chemotherapy
combination immunotherapy
gastric cancer
oesophageal cancer

Access to Document

https://doi.org/10.1177/17588359221142788

Cite this

@article{e984cfd643314d61a8750081ae54657e,

title = "Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer",

keywords = "checkpoint inhibitor, chemotherapy, combination immunotherapy, gastric cancer, oesophageal cancer",

author = "Sarah Derks and {van Laarhoven}, {Hanneke W. M.}",

note = "Funding Information: Dr. Derks reports advisory/speaker role from; BMS, Servier. Research funding or medical supply from: Incyte, and received research funding from the Dutch Cancer Society, the Netherlands Organisation for Scientific Research (NWO) and Oncode Institute.",

year = "2022",

month = jan,

day = "1",

doi = "https://doi.org/10.1177/17588359221142788",

language = "English",

volume = "14",

journal = "Therapeutic advances in medical oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer

AU - Derks, Sarah

AU - van Laarhoven, Hanneke W. M.

N1 - Funding Information: Dr. Derks reports advisory/speaker role from; BMS, Servier. Research funding or medical supply from: Incyte, and received research funding from the Dutch Cancer Society, the Netherlands Organisation for Scientific Research (NWO) and Oncode Institute.

PY - 2022/1/1

Y1 - 2022/1/1

KW - checkpoint inhibitor

KW - chemotherapy

KW - combination immunotherapy

KW - gastric cancer

KW - oesophageal cancer

UR - http://www.scopus.com/inward/record.url?scp=85144538036&partnerID=8YFLogxK

U2 - https://doi.org/10.1177/17588359221142788

DO - https://doi.org/10.1177/17588359221142788

M3 - Editorial

C2 - 36544539

SN - 1758-8340

VL - 14

JO - Therapeutic advances in medical oncology

JF - Therapeutic advances in medical oncology

ER -

Can we do without chemotherapy? A perspective on the combinations nivolumab-chemotherapy and nivolumab–ipilimumab in metastatic gastric and esophageal cancer

Keywords

Access to Document

Other files and links

Cite this